Picici direct Research

CMP: ₹ 224

Target: ₹ 250 (11%) T

Target Period: 12 months

HOLD

December 15, 2021

Outlines capital allocation path...

About the stock: ITC is the biggest cigarettes & second largest FMCG company in India with \sim 78% market share in cigarettes & presence in staples, biscuits, noodles, snacks, chocolate, dairy products & personal care products.

- The company is also present in paperboard, printing & packaging business with revenues of ₹ 4549 crore, agri business with ₹ 8001 crore
- ITC has more than 200 manufacturing facilities in India. It has a distribution reach of over 6.6 million retail outlets across various trade channels & strong 25 brands across various categories

Key Highlights of analyst meet: We attended ITC's analyst meet on December 14, 2021. The management reiterated its strategies & focal points.

- Legal cigarettes constitute 8% of tobacco consumption & 80% of taxes
- FMCG business includes 25+ mother brands across foods, personal care & stationary products categories
- Hotels capex would be limited to ongoing expansions; open to M&A in FMCG & Infotech business

What should investors do? ITC's share price has given near zero return in the last five years (from ₹ 225 in December 2016 to 225 in December 2021)

• We continue to maintain our HOLD rating on the stock

Target Price and Valuation: We value the stock at ₹ 250 on SOTP basis valuing the cigarettes business at 12x FY24 earnings & FMCG business at 5x FY24 sales.

Key triggers for future price performance:

- FMCG business growing at a sustained pace with continuous improvement in margins. Opportunity size of foods portfolio is large
- Duties & taxes on cigarettes to remain stable given increasing prevalence of illicit & contraband cigarettes
- Strong growth expected in paperboard business with strong demand from user industry after Covid-19 recovery

Alternate Stock Idea: We like Zydus Wellness in our FMCG coverage


- It is growing at a steady pace in nascent categories with strong presence in health, nutrition space & margin expansion possibilities
- Trading at significant discount to FMCG peers. BUY with a TP of ₹ 2,800



Particulars	
Particulars (₹ crore)	Amount
Market Capitalization	2,75,345.3
Total Debt (FY21)	56.6
Cash and Investments (FY21)	18,048.2
EV	2,57,353.7
52 week H/L (₹)	265 / 196
Equity capital	1,230.9
Face value (₹)	1.0

Shareholding pattern														
(in %)	Dec-20	Mar-21	Jun-21	Sep-21										
Promoter	0.0	0.0	0.0	0.0										
FII	13.3	12.8	11.7	10.8										
DII	42.9	42.5	42.4	43.7										
Others	43.8	44.7	45.9	45.5										





Recent event & key risks

- ITC's annual consumer spend on FMCG brands is ~₹ 22000 core
- Key Risk: (i) Any increase in cigarette taxation in Budget (ii) elongated period of FMCG margin improvement

Research Analyst

Sanjay Manyal sanjay.manyal@icicisecurities.com

Key Financial Summary							
Key Financials	FY20	FY21 5 Ye	ear CAGR (%)	FY22E	FY23E	FY24E	CAGR (FY21-24E)
Net Sales	46323.7	48151.2	5.9	53460.9	58208.2	64423.7	10.2%
EBITDA	17904.3	15522.5	2.5	19244.1	21892.3	24417.6	16.3%
EBITDA Margin %	38.7	32.2		36.0	37.6	37.9	
Net Profit	15136.1	13031.6	6.9	14620.2	16676.1	18632.6	12.7%
EPS (₹)	12.5	10.7	6.9	12.0	13.7	15.3	12.7%
P/E	18.0	20.9		18.6	16.3	14.6	
RoNW %	23.8	22.1		24.2	26.2	27.6	
RoCE (%)	29.4	28.2		31.4	34.1	36.0	

Company Update

Source: Company, ICICI Direct Research

Key takeaways from analyst meet on December 14, 2021

Analyst Meet update: Open to M&A in FMCG, IT businesses

We attended ITC's analyst meet on December 14, 2021 to get an understanding of the management's future strategies about business growth, margins territory of FMCG business, structure of hotels business, M&A possibilities & capital allocation. Some of the key highlights of the analyst meet:

- Legal cigarette industry accounts for 8% of total tobacco consumption but contributes 80% of government tax revenue. Per capita consumption of cigarettes is one of the lowest in the world
- High tax incidence leads to sub-optimal tax revenue for the government with illicit & contraband cigarettes gaining prominence during high tax rate scenario. During FY13-17, tax increased by 15.7% while government tax revenue increased by merely 4.7% whereas during April 2018 to January 2020, there was no change in taxation & tax revenue increased by 10.2%
- In the cigarette business, the company has leading brands in every segment with more than total 50+ brands. The company's distribution reach is closer to 7.1 million outlets. Total 11% of volumes comes from new launches
- There is no data to suggest that cigarette consumption is trending down structurally. In fact, cigarettes sales have come back closer to pre-Covid levels. The growth levers in the categories are volumes, pricing & mix. Increase in taxation is largely passed on in terms of price increase but volumes and mix are preferred levers during a stable taxation scenario. Product mix for cigarettes category is getting richer with 11% of volumes contributed by new products
- In the FMCG business, consumer spend for the company's brand is ₹ 22000 crore. The company's brands are market leader in atta, cream biscuits, bridges snacks and notebook categories. Its brands are No. 2 in noodles & instant sticks category
- FMCG business margins have increased by 640 bps in the last four years while ITC has been able to maintain its operating margins in H1FY22 despite high commodity inflation in edible oil, Kraft paper & soap noodle. Classmate & Mangaldeep brands are double digit margins brand. With focus on adjacencies of major brands, margins territory is moving upwards
- The company is focusing on adjacencies to leverage mother brand (Aashirwad, Sunfeast, Yippie, Bingo & Savlon). It is also building future brands in floor cleaners, juices, chocolates, dairy, deodorants and ready to eat foods (RTE)
- The growth potential in FMCG categories like snacks, spices, pulses, biscuits, branded atta, noodles, deodorants. floor cleaners, hand wash & body wash is 4-6x in the next decade
- The company has acquired brands like Savlon, Nimyle & Sunrise in the last five years whereas it has divested or shrunk brands like John Players, Wills lifestyle & Superia (shampoo) brands
- The Savlon brand has grown 14x (₹ 1000 crore consumer spends) since acquisition whereas Nimyle has grown 5x since acquisition. Savlon's margins have improved by 600 bps in the last five years. Though hygiene category sales have come down from peak, it is still substantially higher compared to pre-Covid levels
- Media spends towards FMCG brands are driven through digital channels, which is now 16% of the overall media spends
- FMCG business distribution reach has increased by 1.2x to 6.6 million retail outlets in last five years. Moreover, direct reach & stockist network has also increased by 1.4x & 6x respectively in similar period

- In agri business, the company is looking to move up the value chain & focusing on value added ingredient & niche products like spices, fruits, vegetable.
- In hotels business, occupancy levels have reached pre-Covid levels. Leisure hotels occupancies are high whereas business travel hotels are still at 40-50% of the pre-Covid levels
- In paperboard business, the company is focussing on speciality papers, pulp import substitution & scale up of value added product portfolio
- The opportunity in infotech business is immense. The company is open to M&A in the infotech business. It is open to listing possibilities
- The company keeps large wheat inventories to sharpen buying & timing of procurement. No debtors in general trade given it is cash & carry model
- Capex for FY21 was ₹ 1600 crore. Average capex per years would be ₹ 3000 crore per annum for the next three years. Of this, 35-40% would be for FMCG business, 25-30% for paper, paperboard business, 10% for the Hotels business mainly for ongoing projects. Rest of the capex amount would be spending on enhancing digital capabilities & infrastructure
- The company would continue to maintain 80-85% dividend payout and would prefer maintaining ordinary dividend instead of giving special dividend. Total cash on the books of ₹ 25000 crore would not increase, going forward
- De-merger plan of hotels business would be taken at an appropriate time once the business stabilises from the current disruption. The company is actively pursuing M&A opportunity in the FMCG & IT space
- The company is largest investor in PLI for foods, RTE & marine space. ITC would be focusing on exports of FMCG products in different countries largely catering to overseas Indians

Exhibit 1: Peer Comp	arisor	1																	
Sector / Company	CMP TP M Cap Sales growth (%)		EBITDA Margins (%) P/E(x)						RoE (%)			RoCE (%)							
Sector / company (₹) (₹)		(₹)	Rating	(₹ Cr)	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Hindustan Unilever (HINLEV)	2321	2750	Hold	582416	12.9	9.1	8.4	25.6	26.2	26.3	63.0	55.9	51.0	19.5	21.5	23.0	25.0	27.6	29.5
Nestle (NESIND)	19203	20450	Hold	183217	11.1	9.4	10.4	24.8	25.1	25.6	76.0	68.0	60.5	87.8	86.3	83.1	54.9	56.4	57.5
VST Industries (VSTIND)	3148	3700	Hold	5334	4.6	8.3	7.5	36.5	36.2	36.2	16.5	15.5	14.1	32.8	35.7	41.2	44.2	47.7	55.1
ITC Limited (ITC)	224	250	Hold	275345	11.1	8.9	10.7	36.0	37.6	37.9	18.6	16.3	14.6	24.2	26.2	27.6	30.6	34.2	36.8


Source: Company, ICICI Direct Research

ITC is witnessing a recovery in cigarettes volumes & on full year basis FY23 volumes should be at the FY20 levels. We believe stable taxation would aid cigarette volume growth, going forward. FMCG business has witnessed continuous improvement in margins over the last four years. With focus on adjacencies of power brands and scale up newer categories, operating margins would improve over the next five years. We believe the company would be able to improve FMCG segment operating margins by 150-200 bps every year. Further, the possibility of de-merger of hotels, FMCG & infotech business can add shareholder's values in the longer run. Though, we remain optimistic on FMCG business growth & margin prospects de-rating of the cigarettes business globally due to emergence of e-cigarettes poses a greater threat. We maintain our **HOLD** rating and revise our target price on the stock to ₹ 250.


Source: ICICI Direct Research, Company

ICICI Securities | Retail Research










Source: ICICI Direct Research, Company

Exhibit 4: FMCG revenue (₹ crore) and growth (%) trend 13.9 23000 16 13.9 21000 12.4 14 . 19000 10.5 12 17000 10 7.9 7.8 15000 8 13000 6 11000 4 9000 7000 2 5000 n FY19 FY21 FY22E FY23E FY24E FY17 FY18 FY20 Revenues (₹ crore) Revenue Growth (%)



EBIT (₹ crore)

Source: ICICI Direct Research, Company

Source: ICICI Direct Research, Company

Exhibit 5: FMCG EBIT (₹ crore) trend

Source: ICICI Direct Research, Company

Exhibit 6: Hotel revenue (₹ crore) and growth (%) trend






Exhibit 7: Paperboards revenue (₹ crore) and growth (%)



Source: ICICI Direct Research, Company




ICICI Direct Research





Source: ICICI Direct Research, Company

Source: ICICI Direct Research, Company



ICICI Direct Research






Source: ICICI Direct Research, Company

Source: ICICI Direct Research, Company






revenues Legal Cigarettes: ~8% of tobacco consumption Vs. ~80% of tax revenue h **Consumption Share** Tax Revenue Share Surge in illicit trade ie loss to Exchequ Other Tobaco Products 923 se impact on far Consumption Sha Tax Revenue Shar tory & Taxati on policy \rightarrow Imp ative to Realise th

Exhibit 15: An 8% tobacco consumption vs. 80%

Source: ICICI Direct Research, Company



Source: Company, ICICI Direct Research

Exhibit 14: High tax incidence on cigarettes lead to sub-

tax

Financial Summary

Exhibit 17: Profit and lo	ss statem	ent		₹ crore
(Year-end March)	FY21	FY22E	FY23E	FY24E
Total operating Income	48,524.5	53,922.0	58,715.4	64,981.6
Growth (%)	3.7	11.1	8.9	10.7
Raw Material Expenses	19,974.6	20,387.5	21,144.1	22,634.0
Employee Expenses	2,821.0	3,135.3	3,461.9	3,885.1
Marketing Expenses	0.0	956.5	1,038.6	1,273.8
Administrative Expenses	0.0	1,541.1	1,788.7	2,229.2
Excise Duty	3039.4	3343.4	3677.7	4045.5
Other expenses	7,167.1	5,314.1	5,712.2	6,496.4
Total Operating Expenditure	33,002.1	34,677.9	36,823.2	40,564.0
EBITDA	15,522.5	19,244.1	21,892.3	24,417.6
Growth (%)	-13.3	24.0	13.8	11.5
Depreciation	1,561.8	1,531.6	1,571.6	1,611.6
Interest	47.5	52.9	57.6	63.9
Other Income	3,251.0	1,886.1	2,031.2	2,167.8
PBT	17,164.2	19,545.8	22,294.2	24,909.9
Total Tax	4,132.5	4,925.5	5,618.1	6,277.3
PAT	13,031.6	14,620.2	16,676.1	18,632.6
Growth (%)	-13.9	12.2	14.1	11.7
EPS (₹)	10.7	12.0	13.7	15.3

Exhibit 18: Cash flow state	₹	crore		
(Year-end March)	FY21	FY22E	FY23E	FY24E
Profit After Tax	13,207.5	14,620.2	16,676.1	18,632.6
Add: Depreciation	1,561.8	1,531.6	1,571.6	1,611.6
(Inc)/dec in Current Assets	-1,450.3	-2,350.3	4.0	-1,720.6
Inc/(dec) in CL and Provisions	1,055.4	453.3	-177.2	1,110.4
CF from operating activities	11,494.0	14,254.8	18,074.5	19,634.0
(Inc)/dec in Investments	0.0	-9,019.9	-1,951.0	-2,554.3
(Inc)/dec in LT loans & advance	0.0	0.0	0.0	0.0
(Inc)/dec in Fixed Assets	-2,176.3	-2,681.0	-1,020.0	-1,020.0
Others	0.0	0.0	0.0	0.0
CF from investing activities	6,497.9	-4,220.2	-3,071.0	-3,674.3
Issue/(Buy back) of Equity	-2.3	0.0	0.0	0.0
Inc/(dec) in loan funds	-52.0	10.0	10.0	10.0
Dividend paid & dividend tax	-18,629.3	-13,232.0	-13,539.7	-14,770.6
Others	14.0	18.4	24.7	23.5
CF from financing activities	-18,378.9	-13,203.6	-13,505.0	-14,737.1
Net Cash flow	-387.1	-3,169.0	1,498.6	1,222.6
Opening Cash	561.4	174.3	-2,994.7	-1,496.1
Cash with Bank	3,827.2	3,827.2	3,827.2	3,827.2
Closing Cash	4,001.5	832.5	2,331.1	3,553.7

Source: Company, ICICI Direct Research

Source: Company, ICICI Direct Research

Exhibit 19: Balance Shee				₹ crore
(Year-end March)	FY21	FY22E	FY23E	FY24E
Liabilities				
Equity Capital	1,230.9	1,230.9	1,230.9	1,230.9
Reserve and Surplus	57,773.7	59,162.0	62,298.3	66,160.4
Total Shareholders funds	59,004.6	60,392.8	63,529.2	67,391.2
LT Borrowings & Provisions	5.3	15.3	25.3	35.3
Deferred Tax Liability	1,727.7	1,727.7	1,727.7	1,727.7
Others Non-current Liabilitie:	396.4	414.8	439.5	462.9
Total Liabilities	61,134.0	62,550.6	65,721.7	69,617.2
Assets				
Gross Block	34,960.5	38,290.5	39,290.5	40,290.5
Less: Acc Depreciation	14,809.5	16,341.2	17,912.8	19,524.4
Net Block	20,150.9	21,949.3	21,377.7	20,766.1
Capital WIP	3,330.0	1,000.0	1,000.0	1,000.0
Net Intangible Assets	2,731.2	2,751.2	2,771.2	2,791.2
Non-current Investments	12,950.4	21,970.2	23,921.2	26,475.5
LT loans & advances	2.4	2.4	2.4	2.4
Current Assets				
Inventory	9,470.9	10,252.8	10,365.9	11,472.7
Debtors	2,090.4	2,929.4	2,551.6	2,824.1
Loans and Advances	2.8	6.0	6.6	7.3
Other Current Assets	2,203.2	2,929.4	3,189.5	3,530.1
Cash	4,001.5	832.5	2,331.1	3,553.7
Current Investments	14046.7	7046.7	7046.7	7046.7
Current Liabilities	10,174.2	10,627.4	10,450.3	11,560.7
Creditors	4,119.5	4,687.0	3,986.9	4,412.6
Provisions	169.1	30.4	33.1	36.6
Short term debt & other CL	5,885.6	5,910.1	6,430.3	7,111.5
Application of Funds	61,134.0	62,550.6	65,721.7	69,617.2

Source: Company, ICICI Direct Research

Exhibit 20: Key ratios				
(Year-end March)	FY21	FY22E	FY23E	FY24E
Per share data (₹)				
EPS	10.7	12.0	13.7	15.3
Cash EPS	12.0	13.3	15.0	16.7
BV	48.6	49.7	52.3	55.5
DPS	10.8	11.0	12.0	14.0
Cash Per Share	3.3	0.7	1.9	2.9
Operating Ratios (%)				
EBITDA Margin	32.0	35.7	37.3	37.6
PBT / Total Operating income	35.4	36.2	38.0	38.3
PAT Margin	26.9	27.1	28.4	28.7
Inventory days	71.8	70.0	65.0	65.0
Debtor days	15.8	20.0	16.0	16.0
Creditor days	31.2	32.0	25.0	25.0
Return Ratios (%)				
RoE	22.1	24.2	26.2	27.6
RoCE	28.2	31.4	34.1	36.0
RolC	25.6	30.6	34.2	36.8
Valuation Ratios (x)				
P/E	20.9	18.6	16.3	14.6
ev / Ebitda	17.5	14.3	12.5	11.1
EV / Net Sales	5.6	5.1	4.7	4.2
Market Cap / Sales	5.7	5.2	4.7	4.3
Price to Book Value	4.6	4.5	4.3	4.0
Solvency Ratios				
Debt/EBITDA	0.0	0.0	0.0	0.0
Debt / Equity	0.0	0.0	0.0	0.0
Current Ratio	2.7	2.2	2.2	2.2
Quick Ratio	1.8	1.2	1.2	1.2

Source: Company, ICICI Direct Research

Exhibit 21: ICICI Direct coverage universe (FMCG)

	CMP	CMP TP M Cap		P TP M Cap EPS (₹) P/E (x)						Pric	e/Sales	(x)	R	oCE (%)	RoE (%)			
	(?)	(₹)	Rating	(₹ Cr)	FY21	FY22E	FY23E	FY21	FY22E	FY23E	FY21	FY22E	FY23E	FY21	FY22E	FY23E	FY21	FY22E	FY23E
Colgate (COLPAL)	1,449	1,800	Buy	42,088	38.1	38.3	41.1	38.1	37.8	35.2	8.7	8.1	7.5	106.4	110.5	113.2	88.8	84.8	87.0
Dabur India (DABIND)	573	745	Buy	1,05,726	9.6	10.5	12.1	59.8	54.4	47.4	11.1	9.6	8.7	24.5	25.7	27.3	22.1	22.2	23.3
Hindustan Unilever (HINLEV)	2,321	2,750	Hold	5,82,416	33.9	39.3	44.3	68.6	59.0	52.3	12.9	11.4	10.5	18.9	25.0	27.6	17.1	19.5	21.5
ITC Limited (ITC)	224	250	Hold	2,75,345	10.7	12.0	13.7	20.9	18.6	16.3	5.7	5.2	4.7	28.2	31.4	34.1	22.1	24.2	26.2
Jyothy Lab (JYOLAB)	150	170	Hold	5,728	5.2	5.0	6.7	28.9	30.2	22.5	3.0	2.7	2.4	26.0	21.5	27.3	20.4	18.8	23.7
Marico (MARLIM)	513	685	Buy	73,541	9.3	10.2	11.4	55.2	50.4	44.9	9.1	7.6	7.3	40.3	43.0	47.3	37.0	38.7	41.2
Nestle (NESIND)	19,203	20,450	Hold	1,83,217	216.0	249.9	279.6	88.9	76.8	68.7	13.8	12.4	11.3	50.9	54.9	56.4	86.5	87.8	86.3
Tata Consumer (TATGLO)	746	910	Buy	72,703	10.1	11.8	14.1	73.9	63.4	53.0	6.3	5.8	5.3	8.0	8.9	9.9	6.4	7.2	8.3
VST Industries (VSTIND)	3,148	3,700	Hold	5,334	201.3	208.8	223.1	15.6	15.1	14.1	4.8	4.6	4.2	43.4	44.2	47.7	33.0	32.8	35.7
Varun Beverage (VARBEV)	902	1,020	Buy	36,780	8.4	16.0	20.3	107.8	56.2	44.3	5.7	4.3	3.9	10.9	19.6	23.4	10.3	17.2	18.9
Zydus Wellness (ZYDWEL)	1,911	2,800	Buy	13,449	18.7	56.2	67.8	102.4	34.0	28.2	7.2	6.4	5.8	6.2	7.3	8.6	5.5	7.5	9.0
Source: Bloomberg, ICICI Direc	et Researd	ch																	

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according -to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15% Hold: -5% to 15%; Reduce: -15% to -5%; Sell: <-15%



Pankaj Pandey

Head – Research

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com pankaj.pandey@icicisecurities.com

ANALYST CERTIFICATION

I/We, Sanjay Manyal (MBA Finance) Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavor to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. (CLG Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICLC Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.